A Visit to the Institute of Stem Cell and Translational Cancer Research (ISCTCR) at Chang Gung Memorial Hospital in Linkou
|
A Visit to the Institute of Stem Cell and Translational Cancer
Research (ISCTCR) at Chang Gung Memorial Hospital in Linkou
The Institute
of Stem Cell and Translational Cancer Research (ISCTCR) at Chang
Gung Memorial Hospital in Linkou was established in December 2013.
Prof. John Yu, former director of the Genomics Research Center of
the Academia Sinica, along with Prof. Alice Lin-Tsing Yu, former
deputy director of the Genomics Research Center of the Academia
Sinica, were specifically invited to serve as the director and the
deputy director of the ISCTCR respectively. Together they lead a
research team consisting of 60 scholars and researchers
investigating stem cells and cancer, as well as translational and
regenerative medicine and cancer treatment.
Under the
guidance and supervision of Prof. Fu Chan Wei, academician of
Academia Sinica, Prof. Daniel Tsun-Yee Chiu, dean of the Office of
Research and Development, Prof. Chih-Wei Yang, dean of the College
of Medicine, and Prof. Kwang-Huei Lin, associate dean of the College
of Medicine, headed a delegation of approximately 20 scholars and
researchers from the College of Medicine and the College of
Engineering visiting the well-reputed ISCTCR. This visit took an
important step toward the application of Chang Gung University’s
fundamental research on the clinical treatment, as well as toward
the advancement in the management of laboratories and research
teams. Prof. John Yu gave the delegation a tour of the laboratories
as well as a thorough explanation of the facilities and equipment,
including the world-leading device such as confocal microscope,
high-sensitivity LC-MS (liquid chromatography-mass spectrometry),
high-speed fluorescence activated cell sorter/analyzer, and dozens
of pathological, molecular-biological device and cell analyzers.
Then Prof. John Yu and Prof. Alice Lin-Tsing Yu delivered a
presentation on the current research projects of their teams,
including GD2 targeted therapy, and Globo H vaccine and
phosphoproteomic analysis of breast cancer stem cells. Assistant
research fellows Dr. Jung-Tung Hung, Dr. Yuh-Jin Liang, and Dr.
Ming-Yi Ho also introduced their research work on Glycoimmunology
and molecular mechanisms of breast cancer stem cell, etc.
The ISCTCR has been working on the development and innovation of the core technology in glycomics analysis. It is hoped that more patients will benefit from the application of Chang Gung University research teams’ fundamental research in stem cells on the clinical treatment. It is also expected that Chang Gung research teams will be leading worldwide cancer research and treatment. |